Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Noopept
GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester
A synthetic dipeptide-derived nootropic developed in Russia, structurally related to the racetam family but approximately 1000x more potent by weight. Approved as a prescription drug in Russia for cognitive impairment.
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
Modulates AMPA and NMDA glutamate receptors, enhancing long-term potentiation (LTP) — the cellular basis of learning and memory. Increases BDNF and NGF expression in the hippocampus. Also has anxiolytic properties via modulation of inhibitory neurotransmission.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
- Cognitive enhancement
- Memory improvement
- Neuroprotection
- Anxiety reduction
- Post-concussion recovery
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- Headache (most common)
- Irritability at high doses
- Insomnia if taken late in day
- Limited Western clinical data
- Long-term safety unknown
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
No FDA regulatory category. Available as a research chemical in the US. Approved as a prescription drug in Russia. Not a dietary supplement under US law.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.